tbuckley/cabot-search huggingface dataset:
Abstract 17817: Does a Repaired Type A Dissection Turn into a Medical Type B Dissection? Lessons From IRAD
Authors: Kevin K Varughese, Magnus Larsen, Kevin M Harris, Mark D Peterson, Rossella Fattori, Stuart Hutchison, Gilbert R Upchurch, Marek P Ehrlich, Reed E Pyeritz, Daniel G Montgomery, Santi Trimarchi, Christoph A Nienaber, Eric M Isselbacher, Kim A Eagle, Truls Myrmel
Journal: Circulation (2013)

Background: Following complete arch replacement, many Type A acute aortic dissection (TAAAD) patients exhibit a residual false lumen in their descending and/or abdominal aorta. Medically-managed Type B (TBAAD) patients with descending thoracic involvement resemble these post-operative TAAAD cases. We sought to examine whether outcomes differed between these two groups with anatomically-similar remaining dissection flaps. Methods: We analyzed 1017 patients enrolled in the International Registry of Acute Aortic Dissection. Of these, 241 (23.7%) had TAAAD with complete arch replacement; 776 (76.3%) were medically-managed TBAAD patients with most proximal extension in the descending aorta. Results: TAAAD patients were younger (58.0 ± 13.2 v. 64.9 ± 13.7 years, p<0.001) and more often male (80.1% v. 60.3%, p<0.001). Of the 418 (45.4%) with intimal tear identified, the tear was located in the descending aorta and therefore not resected in 4.1% of TAAAD patients, versus 39.9% of their TBAAD counterparts. Additio...
PRECEDENT AND INCIDENT ATRIAL FIBRILLATION ARE ASSOCIATED WITH INCREASED MORTALITY IN PULMONARY EMBOLISM: FINDINGS FROM A MULTINATIONAL COHORT STUDY
Authors: Behnood Bikdeli, Jorge del Toro, David Jimenez, Gregory Piazza, Augustina Rivas, Jose Luis Fernandez-Reyes, Angel Sampériz, Remedios Otero, José María Suriñach, Carmine Siniscalchi, Javier Miguel Martín-Guerra, Joaquín Castro, Samuel Goldhaber, Gregory Y.H. Lip, Manuel Monreal
Journal: Journal of the American College of Cardiology (2020)
TRANSCATHETER MITRAL VALVE REPAIR WITH MITRACLIP IN PATIENTS WITH ATRIAL FUNCTIONAL MITRAL REGURGITATION: RESULTS FROM A SINGLE CENTER REGISTRY
Authors: Kwame Atsina, Jiunn Yap, Timothy Jordan, Edris Aman, Lily Chen, Thomas W. Smith, Dali Fan, Jason Rogers, Gagan Singh
Journal: Journal of the American College of Cardiology (2020)
Anaesthetist is second doctor this year to be restored to GMC register
Authors: Clare Dyer
Journal: BMJ (2020)

An anaesthetist who was struck off the UK medical register for dishonesty in 2012 has been restored to the register after convincing a tribunal that she is now fit to practise without restrictions.

Mona Hosny is the second doctor who had been struck off for misconduct to be allowed back on the register in 2020.1 Reinstatement is fairly rare, and in 2019 only two doctors who had been erased for misconduct succeeded in applications for restoration.

Hosny, who qualified in Egypt in 1991 and obtained full UK registration in 2006, was suspended from the register in 2011 for creating a fake reference purporting to be from “Dr A,” the clinical …
Early Detection and Prediction of Anthracycline-Induced Right Ventricular Cardiotoxicity by 3-Dimensional Echocardiography
Authors: Rui Zhao, Fang Shu, Chujie Zhang, Feiyan Song, Yuchen Xu, Ye Guo, Kai Xue, Jinyi Lin, Xianhong Shu, David H. Hsi, Leilei Cheng
Journal: JACC CardioOncology (2020)

The purpose of this study was to assess the associations between 3-dimensional echocardiography (3DE)-derived changes in right ventricular (RV) volumes and strains with subsequent RV cardiotoxicity in patients treated with anthracyclines.Although early detection and prediction of left ventricular (LV) dysfunction has been widely studied in patients receiving anthracyclines, little is known about the early changes in RV size and function in this population.A total of 74 patients with diffuse large B-cell lymphoma who received 6 cycles of anthracycline-based treatment were enrolled. Echocardiography was performed at baseline or before chemotherapy (pre-chemotherapy) (T0); after 2 cycles (T1); after 4 cycles (T2); and at the end of 6 cycles of chemotherapy (T3). Right ventricular end-diastolic volume (RVEDV), end-systolic volume (RVESV), ejection fraction (RVEF), longitudinal free wall strain (RVLFS), and longitudinal septal strain (RVLSS) were quantified by 3DE. RV cardiotoxicity was defined as a relative reduction of >10% in 3D RVEF or a relative reduction of >5% to a value of <45%. Volume status was assessed by inferior vena cava diameter (IVCD) and the estimated right atrial pressure (RAP).Twenty-seven patients developed cardiotoxicity after 6 cycles of chemotherapy (T3). Compared to baseline, increases in 3D RVEDV (58.5 ± 7.7 ml vs. 64.2 ± 7.0 ml; p < 0.001) and RVESV (27.8 ± 4.2 ml vs. 31.3 ± 4.2 ml; p < 0.001) were observed by the end of the fourth cycle of chemotherapy (T2). 3D RVLFS (-27.3 ± 3.1% vs. -24.2 ± 2.6%; p < 0.001) was also decreased at T2 compared to baseline. Statistically significant declines in 3D RVLSS (-26.1 ± 2.5% vs. -22.9 ± 2.7%; p < 0.001) and RVEF (54.0 ± 2.8% vs. 49.8 ± 2.4%; p < 0.001) were only observed at T3. A relative decrease in RVLFS of >12.4% (sensitivity, 78.6%; specificity, 82.6%; area under the curve (AUC), 0.80; p ＜ 0.001); and a relative increase in RVESV of >13.2% (sensitivity, 71.4%; specificity, 71.7%; AUC, 0.76; p ＜0.001) from baseline to T2 predicted subsequent RV cardiotoxicity at T3. IVCD and RAP did not change significantly over time.3DE-derived measurements of RV strain and volume were associated with subsequent changes in RVEF. With further study, RVLFS and RVESV could potentially be used to predict subsequent declines in RVEF with anthracyclines.
Do human rhinovirus infections and food allergy modify grass pollen-induced asthma hospital admissions in children? [Letter to the Editor]
Authors: Bircan Erbas, Shyamali Dharmage, Mimi Tang, Muhammad Akram, Katrina Allen, Don Vicendese, Janet Davies, Robin Hyndman, Ed Newbigin, Philip Taylor, Philip Bardin, Michael Abramson
Journal: Journal of Allergy and Clinical Immunology (2015)
Profiling gene expression in the human dentate gyrus granule cell layer reveals insights into schizophrenia and its genetic risk
Authors: Andrew E. Jaffe, Daniel J. Hoeppner, Takeshi Saito, Lou Blanpain, Joy Ukaigwe, Emily E. Burke, Leonardo Collado-Torres, Ran Tao, Katsunori Tajinda, Kristen R. Maynard, Matthew N. Tran, Keri Martinowich, Amy Deep-Soboslay, Joo Heon Shin, Joel E. Kleinman, Daniel R. Weinberger, Mitsuyuki Matsumoto, Thomas M. Hyde
Journal: Nature Neuroscience (2020)
Prescription Drugs Switched to OTC
Authors: Rebecca Voelker
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MESENCHYMAL PRECURSOR CELLS IN LVAD RECIPIENTS: DOES HF ETIOLOGY MAKE A DIFFERENCE?
Authors: Y. Joseph Woo, Terrance M. Yau, Stephanie Pan, Kenneth Borow, Carmelo Milano, Doris Taylor, Helena Chang, Anuradha Lala, Michael Acker, Craig Selzman, John Kern, Judy Hung, Patrick T. O'Gara, Eric Rose, Silviu Itescu, Wendy Taddei-Peters, Marissa Miller, Mary E. Marks, Emilia Bagiella, Annetine Gelijns, Alan Moskowitz, Donna Mancini, Francis Pagani
Journal: Journal of the American College of Cardiology (2020)
CLO20-052: Hospitalization and Supportive Care Medication (SCM) Utilization Among Patients Treated With Talazoparib (TALA) Monotherapy: An Integrated Analysis of Five Clinical Trials (Phase 1-3) in Advanced Cancers
Authors: Lida Mina, Ruben G.W. Quek, Johannes Ettl, Ying Chen, Miguel Martin, Zev A. Wainberg, Johann S. de Bono, Sara A. Hurvitz, Hope S. Rugo
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-052: Hospitalization and Supportive Care Medication (SCM) Utilization Among Patients Treated With Talazoparib (TALA) Monotherapy: An Integrated Analysis of Five Clinical Trials (Phase 1-3) in Advanced Cancers" published on 20 Mar 2020 by National Comprehensive Cancer Network.
OUTCOMES OF SPORTS PARTICIPATION FOR PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY AND IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS: DATA FROM THE ICD SPORTS REGISTRY
Authors: Barry Maron, Usama Daimee, Brian Olshansky, David S. Cannom, Hein Heidbuchel, Lisa Salberg, Michael Ackerman, Francois Carre, N.A. Mark Estes, Ian Law, Mark S. Link, Elizabeth Saarel, Matthias Wilhelm, Geliang Gan, Rachel J. Lampert
Journal: Journal of the American College of Cardiology (2020)
Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy
Authors: S. M. Ali, F. J. Esteva, M. Fornier, J. Gligorov, L. Harris, W. J. Kostler, D. Luftner, M. F. Pichon, C. Tse, A. Lipton
Journal: Journal of Clinical Oncology (2006)

500 Background: Trastuzumab monotherapy has a 34% objective response rate (ORR) in patients with HER-2/neu IHC 3+ or FISH-positive first-line metastatic breast cancer (C. Vogel et al, JCO 20:719–726, 2002). Predicting response and survival to trastuzumab-based therapy is an unsolved problem. The HER-2/neu extracellular domain (ECD) is released after cleavage by the ADAM metalloproteinases, and the remaining membrane-bound internal domain is constitutively activated. Trastuzumab inhibits cleavage of the HER-2/neu ECD. Methods: A pooled analysis of 7 trials of first-line trastuzumab therapy (with or without chemotherapy) with serial serum HER-2/neu levels were included. The FDA-approved HER-2/neu ELISA (Oncogene Science/Bayer HealthCare) was used to determine serum HER-2/neu levels. A pretreatment and post-treatment serum (16–120 days) from 307 patients was available. 236 patients had data on overall survival. Kaplan Meier Life table analysis was performed to compare duration of response (DRP), time to progression (TTP), and overall survival (OS). Results: The median decrease in serum HER-2/neu levels for all patients was 31.0% (Range: 98% decrease to 239% increase). Patients with &gt; 20% decrease in HER-2/neu levels had a significantly higher objective response rate (ORR, complete + partial response) and longer DRP, TTP and OS. The results were similar regardless of the timing of the second serum draw (≤ 30 days vs. &gt; 30 days) after the start of trastazumab. Conclusion: Patients with &lt; 20% decrease in serum HER-2/neu levels have decreased benefit from trastuzumab therapy. Patients who do not have a significant decrease in serum HER-2/neu levels should be considered for additional HER-2/neu-targeted therapies. [Table: see text] [Table: see text]
Influenza-associated pneumonia as reference to assess seriousness of coronavirus disease (COVID-19)
Authors: Kristin Tolksdorf, Silke Buda, Ekkehard Schuler, Lothar H Wieler, Walter Haas
Journal: Eurosurveillance (2020)

Information on severity of coronavirus disease (COVID-19) (transmissibility, disease seriousness, impact) is crucial for preparation of healthcare sectors. We present a simple approach to assess disease seriousness, creating a reference cohort of pneumonia patients from sentinel hospitals. First comparisons exposed a higher rate of COVID-19 patients requiring ventilation. There were more case fatalities among COVID-19 patients without comorbidities than in the reference cohort. Hospitals should prepare for high utilisation of ventilation and intensive care resources.
HSR20-097: Granulocyte Stimulating Colony Factor Use, Characteristics and Treatment Patterns in the United States: An Updated Analysis by the Biologics and Biosimilars Collective Intelligence Consortium
Authors: Catherine Lockhart, Cara McDermott, James Marshall, Aaron Mendelsohn, Pamala Pawloski, Jeffrey Brown
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-097: Granulocyte Stimulating Colony Factor Use, Characteristics and Treatment Patterns in the United States: An Updated Analysis by the Biologics and Biosimilars Collective Intelligence Consortium" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Effect of BRM promoter variants on survival outcomes of stage III-IV non-small cell lung cancer (NSCLC) patients.
Authors: Sinead Cuffe, Lu Cheng, Abul Kalam Azad, Yonathan Brhane, Dangxiao Cheng, Zhuo Chen, Xin Qiu, Kevin Boyd, Marjan Emami, Natasha B. Leighl, Sandy Der, Wei Xu, Frances A. Shepherd, Ming Sound Tsao, David Reisman, Geoffrey Liu
Journal: Journal of Clinical Oncology (2013)

11057 Background: BRM, a key catalytic subunit of the SWI/SNF chromatin remodeling complex, is a putative tumor susceptibility gene in NSCLC. Loss of BRM expression occurs in 15% of NSCLC, and has been linked to adverse outcome. Recently, our group has shown that variants of two novel BRM promoter insertion polymorphisms (BRM-741, BRM-1321) lead to loss of BRM expression by recruiting histone deacetylases; individuals carrying homozygous variants for both polymorphisms have doubled NSCLC risk; pharmacological reversal of these epigenetic changes is a potentially viable therapeutic strategy. We thus evaluated the effect of BRM promoter variants on survival outcomes of advanced NSCLC patients, where initial clinical trials are likely to be focused. Methods: 564 stage III-IV NSCLC patients were genotyped for the BRM promoter variants using Taqman. Association of BRM variants and overall (OS) and progression-free survival (PFS) were assessed using Cox proportional hazard models adjusted for prognostic variables. Results: Among our patients, 73% were Caucasian, 52% male, median age 63yrs, 55% stage IV disease, and 67% adenocarcinoma. Median OS was 1.6yrs; median follow up, 3.6yrs. The frequency of homozygosity was BRM-741, 23%; BRM-1321, 21%; both, 12%. Homozygous variants of BRM-741 were strongly associated with worse OS (adjusted HR [aHR] 2.3 [p=2x10E-8]) and PFS (aHR 2.0 [p=2x10E-7]) compared to the wild types. Similar findings were observed for BRM-1321 homozygous variants (aHR for OS 1.8 [p=8x10E-5] and aHR for PFS 1.6 [p=2x10E-4]). Carrying homozygous variants of both BRM-741 and BRM-1321 was associated with substantially worse OS (aHR 2.3 [p=1x10E-5]) and PFS (aHR 2.2 [p=3x10E-6]), with similar associations seen among the stage III (aHR for OS 2.3 [p=6x10E-6]) and stage IV (aHR for OS 2.5 [p=5x10E-6]) patients. Conclusions: The same two homozygous BRM promoter variants that are associated with increased risk of NSCLC are also strongly associated with adverse OS and PFS in this cohort of stage III-IV NSCLC patients. Validation of results in a clinical trial dataset is underway, and will better elucidate the prognostic significance of these BRM promoter variants.
Immunohistochemistry to detect EGFR mutation and ALK gene rearrangement in NSCLC bronchoscopic specimens.
Authors: Mengzhao Wang, Qing qing Pan, Pei Zhu
Journal: Journal of Clinical Oncology (2013)

e19135 Background: The discovery of the E746-A750 and L858R antibodies for mutated epidermal growth factor receptor (EGFR) and the D5F3 antibody for the product of the rearranged anaplastic lymphoma kinase (ALK) gene enables immunohistochemistry(IHC) to be applied to the identification of lung cancer. This study aimed to explore the effectiveness of IHC in small specimens and compare it with standard methods. Methods: We collected bronchoscopic specimens of lung adenocarcinoma that were confirmed by pathology; gathered clinical information, including the basic characteristics of patients, staging and differentiation of the tumor, and the amount and proportion of tumor cells; identified mutant EGFR with E746-A750del and L858R antibodies and rearranged ALK with D5F3 antibody (Cell Signaling Technology, USA); and compared their sensitivity and specificity with standard methods. Results: We collected 92 patients¡&amp;hibar; bronchoscopic specimens. All specimens were successfully detected by the Scorpions-ARMS method£€and exon 19 deletion occurred in 15 specimens (16.3%), and exon 21 L858R mutation in 15 specimens (16.3%). In EGFR-IHC, the positive rates of E746-A750del and L858R were 17.8% (16/92) and 21.4% (19/92), respectively. The sensitivity and specificity of E746-A750del (with Scorpions-amplification refractory mutation system (ARMS) as the standard) were 73.3% (11/15) and 93.3% (70/75), respectively, and those of L858R were 93.3% (14/15) and 93.2% (69/74). Neither method was significantly worse than Scorpions-ARMS (p£½1.000 for E746-A750del, p£½0.219 for L858R). FISH detected 6 positive and 71 negative specimens for ALK rearrangement; the other 15 could not be evaluated for various different reasons. In ALK-IHC, the positive rate was 7.8% (6/77; 13 could not be evaluated). The sensitivity and specificity of D5F3 were 50% (3/6) and 100% (71/71), respectively. ALK-IHC showed no difference with the standard method of fluorescence in situ hybridization (FISH). Conclusions: IHC with E746-A750del and L858R antibodies is an economical and convenient method for EGFR mutation detection in small specimens of NSCLC, as is D5F3 monoclonal antibody for ALK-IHC, especially for the primary screening.
Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment
Authors: Hannah Lowes, Angela Pyle, Mauro Santibanez-Koref, Gavin Hudson
Journal: Molecular Neurodegeneration (2020)

Abstract Several studies have linked circulating cell-free mitochondrial DNA (ccf-mtDNA) to human disease. In particular, reduced ccf-mtDNA levels in the cerebrospinal fluid (CSF) of both Alzheimer’s and Parkinson’s disease (PD) patients have raised the hypothesis that ccf-mtDNA could be used as a biomarker for neurodegenerative disease onset and progression. However, how a reduction of CSF ccf-mtDNA levels relates to neurodegeneration remains unclear. Many factors are likely to influence ccf-mtDNA levels, such as concomitant therapeutic treatment and comorbidities. In this study we aimed to investigate these factors, quantifying CSF ccf-mtDNA from the Parkinson’s Progression Markers Initiative in 372 PD patients and 159 matched controls at two time points. We found that ccf-mtDNA levels appear significantly reduced in PD cases when compared to matched controls and are associated with cognitive impairment. However, our data indicate that this reduction in ccf-mtDNA is also associated with the commencement, type and duration of treatment. Additionally, we found that ccf-mtDNA levels are associated with comorbidities such as depression and insomnia, however this was only significant if measured in the absence of treatment. We conclude that in PD, similar to reports in HIV and sepsis, comorbidities and treatment can both influence ccf-mtDNA homeostasis, raising the possibility that ccf-mtDNA may be useful as a biomarker for treatment response or the development of secondary phenotypes. Given that, clinically, PD manifests often decades after neurodegeneration begins, predicting who will develop disease is important. Also, identifying patients who will respond to existing treatments or develop secondary phenotypes will have increased clinical importance as PD incidence rises.
PLATYPNEA-ORTHODEOXIA SYNDROME: KEY PATHOGENETIC ROLE OF PATENT FORAMEN OVALE (PFO) AND DRAMATIC RESPONSE TO PFO CLOSURE
Authors: Farrah Othman, Nicholas Collins, Brian Bailey, Karan Rao, David Tanous, Edmund Lau, David Celermajer, Rachael Cordina
Journal: Journal of the American College of Cardiology (2020)
DIFFERENT PROGNOSTIC IMPACT OF HIGH-SENSITIVITY C-REACTIVE PROTEIN IN ACUTE MYOCARDIAL INFARCTION PATIENTS WITH AND WITHOUT TYPE 2 DIABETES MELLITUS
Authors: Giancarlo Silvio Marenzi, Claudia Lucci, Nicola Cosentino, Jeness Campodonico, Maria Luisa Biondi, Valentina Milazzo, Monica De Metrio, Katia Celentano, Marco Moltrasio, Mara Rubino, Ivana Marana, Marco Grazi, Gianfranco Lauri, Stefano Genovese
Journal: Journal of the American College of Cardiology (2020)
Erratum: Corrigendum: Generation of stable monoclonal antibody–producing B cell receptor–positive human memory B cells by genetic programming
Authors: Mark J Kwakkenbos, Sean A Diehl, Etsuko Yasuda, Arjen Q Bakker, Caroline M M van Geelen, Michaël V Lukens, Grada M van Bleek, Myra N Widjojoatmodjo, Willy M J M Bogers, Henrik Mei, Andreas Radbruch, Ferenc A Scheeren, Hergen Spits, Tim Beaumont
Journal: Nature Medicine (2016)
IMPACT OF TRICUSPID REGURGITATION ON OUTCOMES AFTER MITRACLIP TREATMENT OF SECONDARY MITRAL REGURGITATION: RESULTS FROM THE COAPT TRIAL
Authors: Rebecca Hahn, Federico M. Asch, Neil J. Weissman, Paul A. Grayburn, Saibal Kar, None Kar, Scott Lim, Ori Ben-Yehuda, Bahira Shahim, Shmuel Chen, Mengdan Liu, Bjorn Redfors, Diego Medvedofsky, Rishi Puri, Samir Kapadia, Anna Sannino, JoAnn Lindenfeld, William Abraham, Michael Mack, Gregg Stone
Journal: Journal of the American College of Cardiology (2020)
Efficacy and safety of bevacizumab in nonsquamous non-small cell lung cancer with brain metastases.
Authors: Masao Ichiki, Tsukasa Yoshida, Masayuki Nakamura, Tomomi Kumano, Tomoaki Hoshino
Journal: Journal of Clinical Oncology (2013)

e19134 Background: Patients (pts) with brain metastases were excluded from bevacizumab (Bev) therapy due to a case of fatal cerebral hemorrhage in 1997. However, several trials showed the safety of Bev in pts with inactive (previously treated or asymptomatic) brain metastases, and Bev therapy was recently permitted as practical care for brain metastases in Japan. Methods: We retrospectively identified pts treated with Bev for inactive brain metastases from NSCLC. CT or MRI scans performed at least 6 weeks after Bev therapy were assessed for response. Results: There were 17 pts. All pts had adenocarcinoma. Median age was 66 (range 57-74), male/female= 8/9, PS0/1/2= 3/10/4, 1 st -/2 nd -/3 rd -/4 th -line chemotherapy with Bev = 8/4/4/1, EGFR mutation status; mutated/wild type/unknown=8/7/2; concurrent chemotherapy with Bev: amrubicin (1), pemtrexed (2), cisplatin (carboplatin) + pemetrexed (10), carboplatin + paclitaxel (3), cisplatin + gemcitabine (1); prior chemotherapy: gefitinib (6), erlotinib (3), docetaxel (1), carboplatin + paclitaxel (2), cisplatin + pemetrexed (2), pemetrexed (1); prior therapy for brain metastases: surgery (1), surgery + WBRT (2),WBRT (8), SRS (4), none (2). In 14 pts with evaluable target brain metastases, the response rate for intracranial metastases was 78.6% (95% CI, 49.2-95.4%), and in 15 pts with evaluable target lesions except brain metastases, the response rate for extracranial metastases was 40.0% (95% CI, 16.3-67.7%). Serious toxicities (grade 3/4): hypertension (2/0), proteinuria (0/-). There were 2 bleeding events: one was grade 1 intracraninal hemorrhage, the other was grade 1 bronchopulumonary hemorrhage. Conclusions: Chemotherapy+Bev is effective for pts with inactive brain metastases and is a well-tolerated regimen with a favorable toxicity profile. The updated data including PFS and OS will be presented at the Annual Meeting.